Skip to content
Screener

Shares (Diluted) at other companies

Amgen logo
AmgenAMGN
544M+0.6%
WHW
Whitehawk TherapeuticsWHWK
69.2M+73.4%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
67.4M+34.6%
Eikon Therapeutics, Inc. logo
Eikon Therapeutics, Inc.EIKN
33.7M+1,116%
Arcus Biosciences logo
Arcus BiosciencesRCUS
126.1M+18.4%
Immunome logo
ImmunomeIMNM
113.1M+42.5%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.49B+68.5%
Enterprise value$3.36B+69.4%
P/S15×+10.3×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206357
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Loss from operations(108,544)(84,389)
Other income
Interest income and other income, net10,00512,211
Net loss$(98,539)$(72,178)
Unrealized (losses) gains on marketable securities(2,761)773
Comprehensive loss$(101,300)$(71,405)
Net loss per common share, basic and diluted$(1.11)$(0.82)
Weighted-average common shares outstanding, basic and diluted88,699,75488,356,335

Item 1. Financial Statements (UNAUDITED).

FAQ

What is IDEAYA Biosciences, Inc.'s shares (diluted)?
IDEAYA Biosciences, Inc. (IDYA) reported shares (diluted) of 88.7M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s shares (diluted) changed year-over-year?
IDEAYA Biosciences, Inc.'s shares (diluted) increased by 0.4% year-over-year, from 88.4M to 88.7M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s shares (diluted) has grown at a 26.7% compound annual growth rate (CAGR), from 137.6M to 355M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about IDEAYA Biosciences, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude